Injectable SHR-A1811 with Pyrotinib or SHR-1316 for advanced lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of SHR-A1811 when combined with either Pyrotinib or SHR-1316 in patients with advanced non-small cell lung cancer (NSCLC) that expresses HER2. The trial is structured in two parts: Part A focuses on dose escalation and efficacy exploration of SHR-A1811 with Pyrotinib, while Part B examines the same for SHR-A1811 with SHR-1316. It is an open, multicenter trial designed to assess the potential benefits of these combinations in treating advanced NSCLC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ability to give informed consent, signed and dated IRB/EC approved informed consent, willing and able to comply with treatment planning visits, tests and other procedural requirements
2. When signing the informed consent, the age is 18-75 years old (including both ends), and there is no gender limitation
3. The ECOG score is 0 or 1
4. The expected survival is ≥12 weeks
5. Subjects with advanced or metastatic non-small cell lung cancer
6. Formalin fixed, paraffin-embedded tumor tissue blocks or sections of unstained tumor specimens are provided
7. Subjects who have failed prior standard care or are intolerant to standard care
8. There is at least one measurable lesion
9. Vital organs are functioning well
10. Heart function is good
11. Agree to birth control

Exclusion Criteria:

1. There are untreated or active central nervous system (CNS) tumor metastases
2. Pleural, ascites, or pericardial effusion requiring intervention occurred within 7 days prior to initial administration
3. Systemic antitumor therapy was performed 4 weeks prior to study initiation
4. Prior treatment with antibody-conjugated drugs
5. Received \>30 Gy chest radiation within 6 months prior to initial administration
6. Palliative radiotherapy was completed within 7 days prior to initial administration
7. Failure to recover from toxicity and/or complications of previous interventions to nCI-CTCAE ≤1
8. The half-life of CYP3A4 suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected
9. Received systemic immunosuppressant therapy within 14 days prior to the first study
10. Subjects with known or suspected interstitial pneumonia
11. In the first study, failure to swallow, chronic diarrhea, gastroenteritis, intestinal obstruction, gastrointestinal perforation, postgastrectomy, or colitis, or other medical conditions or special conditions affecting drug administration and absorption occurred within 28 days prior to administration
12. Presence of any active, known or suspected autoimmune disease
13. Have poorly controlled or severe cardiovascular disease
14. Previous or concurrent malignancy
15. Subjects who developed a severe infection within 28 days prior to the first dose
16. Active hepatitis B
17. There were active tuberculosis patients within 1 year before enrollment
18. There is a history of immunodeficiency
19. Live attenuated vaccine was administered within 28 days prior to initial study administration or is expected to be administered during study treatment
20. Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter
21. Major surgery other than diagnosis or biopsy was performed within 28 days prior to initial administration
22. People who are known to be allergic to sir-A1811, pyrrolitinib, or any of the components of SIR-1316
23. History of severe allergic reactions to other monoclonal antibody/fusion protein drugs
24. Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study
25. Uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse and detention
26. Any other conditions that, in the investigator's judgment, may increase the risk of study participation, interfere with study results, or make study participation unsuitable

Where it's running

• Shanghai Chest hospital
  Shanghai, Shanghai Municipality, China Recruiting
• Zhejiang Cancer Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Suqiang Yu
• Email: suqiang.yu@hengrui.com
• Phone: +0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• Long-term survival and AI-based prediction in NSCLC patients treated with immunotherapy

  This study tests whether AI analysis of routine pathology images, along with multi-omics data, can predict long-term survival for people with advanced NSCLC treated with immunotherapy.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07668037

• Tislelizumab use in European patients with NSCLC or ES-SCLC in routine care

  This study looks at how tislelizumab is used in real-world European patients with advanced NSCLC or extensive-stage SCLC and what outcomes are seen in everyday clinical practice.

  Recruiting at 6 sites BeOne Medicines · Córdoba and 5 other locations · NCT07652736

• Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer

  This study tests a treatment combination of Pyrotinib, Trastuzumab and chemo given before surgery to see if it can improve responses in HER2-positive breast cancer patients who have not yet been treated.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07635342

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.